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O B J E C T I V E S The purpose of this study was to determine whether thin-capped ﬁbroatheromata
(TCFA) identiﬁed by virtual histology intravascular ultrasound (VH-IVUS) are associated with major
adverse cardiac events (MACE) on individual plaque or whole patient analysis.
B A C KG ROUND Post-mortem studies have identiﬁed TCFA as the substrate for most myocardial
infarctions. However, little is known about the natural history of individual TCFA and their link with
MACE. VH-IVUS provides a method of identifying plaques in vivo that are similar (although not identical)
to histologically deﬁned TCFA, and has been validated in human atherectomy and post-mortem studies.
METHOD S One hundred seventy patients with stable angina or troponin-positive acute coronary
syndrome referred for percutaneous coronary intervention (PCI) were prospectively enrolled and
underwent 3-vessel VH-IVUS pre-PCI and also post-PCI in the culprit vessel. MACE consisted of death,
myocardial infarction, or unplanned revascularization.
R E S U L T S In all, 30,372 mm of VH-IVUS were analyzed. Eighteen MACE occurred in 16 patients over a
median follow-up of 625 days (interquartile range: 463 to 990 days); 1,096 plaques were classiﬁed, and 19
lesions resulted in MACE (13 nonculprit lesions and 6 culprit lesions). Nonculprit lesion factors associated with
nonrestenotic MACE included VHTCFA (hazard ratio [HR]: 7.53, p 0.038) and plaque burden70% (HR: 8.13,
p 0.011). VHTCFA (HR: 8.16, p 0.007), plaque burden70% (HR: 7.48, p 0.001), andminimum luminal area
4 mm2 (HR: 2.91, p  0.036) were associated with total MACE. On patient-based analysis, the only factor
associated with nonrestenotic MACE was 3-vessel noncalciﬁed VHTCFA (HR: 1.79, p  0.004).
CONC L U S I O N S VH-IVUS TCFA was associated with nonrestenotic and total MACE on individual plaque
analysis, and noncalciﬁed VHTCFA was associated with nonrestenotic and total MACE on whole-patient analysis,
demonstrating that VH-IVUS can identify plaques at increased risk of subsequent events. The preservation of the
association between VHTCFA and MACE despite various analyses emphasizes its biological importance. (J Am
Coll Cardiol Img 2011;4:894–901) © 2011 by the American College of Cardiology Foundation
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895T
he majority of myocardial infarctions (MIs)
are caused by specific subtypes of coronary
atherosclerotic plaque. Thus, the substrate for
60% to 70% of MIs are “thin-capped fibro-
theromata” (TCFA), where a thin fibrous cap
65 m) separates a necrotic core from the lumen,
frequently without significant vessel stenosis (1,2).
Cap rupture exposes intraplaque material, resulting
in intravascular thrombosis and vessel occlusion.
See page 902
Although fibroatheromata can be identified at post-
mortem, identifying high-risk plaque subtypes before an
event remains a major challenge.
Radiofrequency, or “virtual histology” intravascu-
lar ultrasound (VH-IVUS) is based upon spectral
analysis of ultrasound backscatter, with different
plaque components exhibiting a defined spectrum
(3). The radiofrequency signal is mathematically
transformed into a color-coded representation, in-
cluding lipid, fibrous tissue, calcification, and ne-
crotic core (4); IVUS pullback allows reconstitution
in 3 dimensions. VH-IVUS spectral analysis corre-
lates well with histopathology (predictive accuracy
87.1%, 87.1%, 88.3%, and 96.5% for fibrous, fibro-
fatty, necrotic core, and dense calcium, respectively)
(5,6). VH-IVUS can also identify VHTCFA (7)
and other plaque subtypes, and follow plaque com-
position after treatment (8).
Although VH-IVUS is promising, little is known
about the link between VH-IVUS–defined plaque
classification or plaque composition and long-term out-
come, a crucial requirement for VH-IVUS to be used for
risk stratification and assessing interventions, with the
recently published PROSPECT (Providing Regional
Observations to Study Predictors of Events in the
Coronary Tree) study being the only other study (9).
urthermore, as major adverse cardiac events
MACE) are often driven by disease in nontarget
essels after percutaneous coronary intervention
PCI), it is unclear whether 3-vessel VH-IVUS is
ore strongly associated with outcome than plaque-
ased VH-IVUS analysis.
M E T H O D S
Patients. The VIVA (Virtual Histology in Vulner-
ble Atherosclerosis) study protocol was approved
y the Cambridgeshire Research and Ethics
ommittee-3 (ref 07/Q0106/47); all participants
ave written informed consent before enrollment.
atients undergoing PCI with either stable angina cr troponin-positive acute coronary syndrome
ACS) were prospectively enrolled. Exclusion cri-
eria were: 1) prior revascularization or unsuitable
or 3-vessel VH-IVUS; and 2) ACS, active inflam-
atory condition, or any form of surgery up to 3
onths before enrollment.
VH-IVUS was performed in all main coronary
rteries (target vessels before and after PCI and also
ontarget vessels) after administration of glyceryl
rinitrate. Data were acquired with 20 MHz Eagle-
ye Gold catheters (Volcano Corporation, Rancho
ordova, California) using motorized pull-back at 0.5
m/s from the most distal safe position to the guide
atheter. Data were captured on S5 consul
oftware version 3.1 (Volcano Corporation),
nd analysis was performed offline by Kra-
ow Cardiovascular Research Institute core
aboratory, using the Volcano Image Anal-
sis Software version 3.0.394. Consequently,
H-IVUS analysis did not influence PCI
rocedure or subsequent management.
Blood was drawn immediately pre-PCI
nd 24 h post-PCI. Core laboratory anal-
sis of samples was performed for troponin-I
cTnI), interleukin-6 (IL-6), interleukin-18
IL-18), high-sensitivity C-reactive protein
hsCRP), neopterin, soluble intracellular ad-
esion molecule-1 (ICAM-1), and mono-
yte chemoattractant protein-1 (MCP-1).
Plaque classiﬁcation. We utilized the fol-
owing plaque classification (Fig. 1), con-
istent with subsequently published VH-
VUS classifications (10): 1) Plaque:
laque burden of 40% vessel cross-
sectional area for 3 consecutive frames. 2)
Fibroatheroma (VHFA): plaque burden
40%, confluent necrotic core 10%
laque cross-sectional area, all for 3 con-
ecutive frames. 3) Thin-capped fibro-
theroma (VHTCFA): fibroatheroma
above) with the confluent necrotic core (10% of
laque cross-sectional area) in contact with vessel
umen for 3 consecutive frames. VHTCFA were
ubdivided into calcified VHTCFA (dense calcium
10% plaque cross-sectional area in 3 consecutive
rames) and noncalcified VHTCFA. 4) Thick-
apped fibroatheroma (VHThCFA): fibroatheroma
ot fulfilling VHTCFA conditions. VHThCFA
ere subdivided into calcified VHThCFA (dense
alcium 10% plaque cross-sectional area in 3
onsecutive frames) and noncalcified VHThCFA.
) Fibrocalcific plaque (VHFCa): plaque with dense
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896consecutive frames, not meeting fibroatheroma def-
inition. 6) Pathological intimal thickening (VHPIT):
plaque not meeting VHFA or VHFCa plaque
definitions and predominantly fibrous tissue.
Culprit lesions were defined according to electro-
cardiographic criteria (ST-segment shift or T-wave
inversion) and angiographic appearances (point of
angiographic maximal stenosis, luminal irregulari-
ties consistent with ulceration, or filling defects
consistent with thrombus) at PCI. Complete cov-
erage by stent was also confirmed on IVUS. Remod-
eling index, thrombus, and plaque rupture were de-
termined according to established definitions (11).
Follow-up and study endpoints. Patients were fol-
owed up for 3 years from enrollment of the first
atient by clinic visits, telephone interview, clinical
atabases, and clinical notes. The composite primary
ndpoint of (total) MACE comprised death, myocar-
ial infarction, and unplanned revascularization (PCI
nd coronary artery bypass surgery, driven by nonre-
tenotic lesions and in-stent restenosis [ISR]). Non-
estenotic MACE comprised a combined endpoint of
eath, myocardial infarction, or unplanned revascular-
Figure 1. Single Frame Examples of Plaque Classiﬁcation by VH
(A) Virtual histology intravascular ultrasound (VH-IVUS) pathologica
capped ﬁbroatheroma (VHThCFA), and (D) thin-capped ﬁbroatherom
areas indicate ﬁbrofatty tissue; red areas indicate necrotic core; andzation, excluding in-stent restenosis-driven events. PStatistical analysis. LESION-BASED ANALYSIS. To as-
sess the effect of NCL factors on nonrestenotic
MACE, a series of Cox proportional hazard regres-
sion models were fitted. Because these analyses con-
tained several lesions per patient, analyses were strat-
ified by patient. This allows patients to have a different
baseline hazard, but within strata, the effects of lesion
characteristics on time to event were assumed com-
mon to all patients. The MACE events occurring
without angiographic follow-up were classified as
“indeterminant” and were excluded. A second analysis
was planned to examine associations between culprit
lesion factors and ISR-driven MACE (excluding de
novo plaque-driven MACE). However, the number
of ISR-driven MACE endpoints was too low for a
valid Cox proportional Hazard regression analysis.
We therefore analyzed the association between all
lesions at baseline (NCL and culprit lesions) with all
MACE endpoints (nonrestenotic and ISR-driven)
using univariate Cox proportional hazard regression
stratified by patient as above.
PATIENT-BASED ANALYSIS. All variables (clinical,
S
mal thickening (VHPIT), (B) ﬁbrocalciﬁc plaque (VHFCa), (C) thick-
VHTCFA). Dark green areas indicate ﬁbrous tissue; lighter green
ite areas indicate dense calcium.-IVU
l inti
a (CI-related, NCL grayscale IVUS, and VH-IVUS
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897parameters) were tested for association with nonre-
stenotic MACE using univariate Cox propor-
tional hazard regression. All p values 0.05 were
onsidered significant.
BIOMARKERS. Biomarker levels at baseline and also
he stenting-related rise in biomarkers (24 h post-
CI minus immediately pre-PCI) were tested for
ssociation with nonrestenotic MACE using uni-
ariate Cox proportional hazard regression. All
values 0.05 were considered significant.
Statistical analysis was performed using SPSS ver-
ion 17.0 (SPSS Inc, Chicago, Illinois). MACE rates
n similarly mixed stable angina and ACS patient
ohorts suggested a 5.8% drug-eluting stent (DES)
nd 28.8% bare-metal stent (BMS) 1-year MACE
ate (12). Our recent stent usage ratio was 2 DES:1
MS. Given the projected 18-month median follow-
p, we expected 20 MACE per 100 patients recruited.
ower calculations suggested that 100 patients would
e required to detect a 20% difference in VHTCFA
ith 80% power and an alpha 0.05. Recruitment of
70 patients was set to allow for lower than expected
ACE rates.
R E S U L T S
Study recruitment and adverse events. One hundred
seventy patients (100 stable angina and 70
troponin-positive ACS) underwent 3-vessel VH-
IVUS. There were 18 MACE in 16 patients: 14
revascularizations (11 PCI and 3 coronary artery
bypass grafting), 2 MIs and 2 deaths. Three pa-
tients’ data (all ACS) were excluded from analysis
after corruption of archived VH-IVUS recordings.
Median follow-up of the remaining 167 patients
was 625 days (interquartile range: 463 to 990 days).
In all, 30,372 mm of VH-IVUS were analyzed.
There were no adverse events related to IVUS
pullbacks.
Lesion-based analysis. Both patients who died
acked angiographic follow-up and, therefore, were
xcluded from the lesion-based analysis. In total,
,096 lesions were analyzed; 19 lesions resulted in
ACE (13 nonrestenotic MACE and 6 ISR-
riven MACE). The number of lesions resulting in
ACE by lesion type (culprit lesion vs. NCL) is
hown in Table 1. Of the 13 NCLs that resulted in
onrestenotic MACE, 9 were in different vessels
rom the original stent, and 4 were in the same vessel:
were 10 mm from the original stent (1 BMS and
DES), and 2 were 40 mm from the original stent
1 BMS and 1 DES). One of the MI MACE was due
o ISR. The other MI did not result in further PCI.There were 931 NCLs, of which 13 resulted in
ACE over a median follow-up of 625 days (1.4%).
ix of the 165 culprit lesions resulted in MACE
3.6%). The following plaque characteristics were
reater or more frequent in NCLs that caused nonre-
tenotic MACE: noncalcified VHTCFA (5 [38%] vs.
69 [18.4%]), p  0.025), MLA 4 mm2, plaque
burden 70%, and remodeling index (Table 2).
The MACE rate was greater for culprit lesions
than for NCL (p  0.003) (Fig. 2A), but this
ifference was lost when plaque burden was 70%
Fig. 2B). Similarly, the MACE rate for noncalci-
ed VHTCFAs was greater for culprit lesions than
or NCL (log-rank p  0.045) (Fig. 2C), with the
ifference lost again when plaque burden was70%
Fig. 2D). The MACE rate for NCLs was greater
or lesions with a plaque burden 70% (log-rank
 0.001) (Fig. 2E), but there was no difference in
rates for culprit lesions with plaque burdens at
baselines above or below 70% (Fig. 2F).
Table 1. Total Number of MACE According to Plaque Subtype
Nonculprit Lesion
MACE/Total
Culprit Lesio
MACE/Total
VHPIT 1/132 (0.8%) 0/17 (0%)
VHFCa 1/92 (1.1%) 0/8 (0%)
Noncalciﬁed VHThCFA 2/100 (2%) 1/17 (5.9%)
Calciﬁed VHThCFA 1/46 (2.2%) 0/8 (0%)
Noncalciﬁed VHTCFA 5/175 (2.9%) 3/35 (8.6%)
Calciﬁed VHTCFA 3/386 (0.8%) 2/80 (2.5%)
Total 13/931 (1.4%) 6/165 (3.6%)
Values are n/N (%).
MACE  major adverse cardiac event; VHFCa  virtual histology intr
ﬁbrocalciﬁc plaque; VHPIT  virtual histology intravascular ultrasound patholo
ing; VHTCFA  virtual histology intravascular ultrasound thin-capped ﬁbroath
virtual histology intravascular ultrasound thick-capped ﬁbroatheroma.
Table 2. Comparison of NCL Parameters for Nonrestenotic MAC
NCL Parameters
No MACE
(n  918)
Nonrestenotic MAC
(n  13)
VHPIT 131 (14.3%) 1 (8%)
VHFCa 91 (9.9%) 1 (8%)
Noncalciﬁed VHThCFA 101 (11.0%) 2 (15%)
Calciﬁed VHThCFA 45 (4.9%) 1 (8%)
Noncalciﬁed VHTCFA 169 (18.4%) 5 (38%)
Calciﬁed VHTCFA 381 (41.5%) 3 (23%)
MLA 4 mm2 251 (27%) 7 (54%)
Plaque burden 70% 169 (18%) 9 (69%)
Remodeling index 1.00 (0.13) 1.14 (0.13)
Plaque volume, mm3 51 (21–127) 196 (106–430)
Thrombus 13 (1.4%) 0 (0%)
Ruptured plaque 13 (1.4%) 0 (0%)
Values are n (%), mean (SD), or median (interquartile range).n Log-Rank
p Value
0.30
0.54
0.43
0.93
0.045
0.16
0.003
avascular ultrasound
gical intimal thicken-
eroma; VHThCFA E
E Log-Rank
p Value
0.54
0.78
0.78
0.79
0.025
0.32
0.021
0.001
0.014
0.004
0.67
0.67MLA  minimum luminal area; NCL  nonculprit lesion; other abbreviations as in Table 1.
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898Associations between NCL and nonrestenotic MACE.
VHTCFA was the only NCL plaque subtype asso-
ciated with nonrestenotic MACE on univariate
analysis (HR: 7.53 [95% confidence interval [CI]:
1.12 to 50.55], p  0.038) (Fig. 3A). Plaque-based
factors associated with nonrestenotic MACE in-
cluded plaque burden 70% (HR: 8.13 [95% CI:
.63 to 40.56], p  0.011) and remodeling index
HR: 2686 [95% CI: 1.94 to 3.72  106], p 
.032) (Fig. 3B).
Associations between all plaques (culprit and NCL) and
total MACE events (nonrestenotic and ISR-driven
events). VHTCFA was the only VH-IVUS plaque
subtype associated with total MACE on univariate anal-
ysis (HR: 8.16 [95% CI: 1.78 to 37.32], p 0.007) (Fig.
3C). Plaque-based factors associated with total MACE
included plaque burden70% (HR: 7.48 [95% CI: 2.50
to 22.31], p 0.001), MLA4 mm2 (HR: 2.91 [95%
CI: 1.07 to 7.91], p  0.036), and the plaque being a
ulprit lesion, as opposed to NCL (HR: 4.43 [95% CI:
.50 to 13.18], p  0.007) (Fig. 3D).
Patient-based analysis of association between NCL
factors and nonrestenotic MACE. No patient-based
linical factors were associated with nonrestenotic
Figure 2. Kaplan-Meier Plot of Cumulative MACE Rates
(A) All lesions, (B) lesions with plaque burden (PB) 70%, (C) all noncalciﬁ
(VHTCFA), (D) noncalciﬁed VHTCFA with PB 70%, (E) nonculprit lesions,ACE (Fig. 4A). Similarly, no stent-related or gray-cale IVUS parameters were associated with nonrest-
notic MACE (Fig. 4B). On whole patient-based
nalysis, the only NCL factor associated with nonre-
tenotic MACE was 3-vessel noncalcified VHTCFA
HR: 1.79 [95% CI: 1.20 to 2.66], p  0.004) (Fig.
C). Biomarker levels measured immediately pre-PCI
ere not associated with nonrestenotic MACE. How-
ver, the PCI-related rise in interleukin-6 and high-
ensitivity C-reactive protein were associated with non-
estenotic MACE on univariate analysis (Fig. 4D).
D I S C U S S I O N
The ability to identify plaque anatomy and compo-
sition in vivo is potentially a powerful method of
predicting subsequent patient outcome. Despite the
wealth of data on the substrate for MI from
post-mortem studies (1,2,10) or animal models
(11), methods that prospectively identify plaques
that subsequently rupture are needed. VH-IVUS
identifies plaque composition and potentially clas-
sifies plaques into low-risk and high-risk subtypes.
However, to date, the potential prognostic rele-
vance of VH-IVUS findings to clinical outcomes in
irtual histology intravascular ultrasound thin-capped ﬁbroatheroma
(F) culprit lesions. MACE  major adverse cardiac event.ed vpatients undergoing PCI has received limited study.
r ab
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899In this prospective study of patients undergoing
3-vessel coronary artery VH-IVUS, NCL VHTCFA
was associated with nonrestenotic MACE, both on
an individual plaque and whole-patient analysis.
Although similar findings have recently been re-
ported from the PROSPECT study on an individ-
ual plaque basis (9), this is the first report of an
association between VH-IVUS–based plaque clas-
sification and nonrestenotic MACE on a whole-
patient basis. This is also the first report of an
association between VH-IVUS–identified plaque
classification and total MACE. The preservation of
this association between VHTCFA and MACE on a
number of different analyses emphasizes the biological
importance of this association, and indicates that
VH-IVUS can identify plaques at increased risk of
subsequent events. In addition, NCL plaque burden
70% and remodeling index were also both strongly
associated with nonrestenotic MACE.
Nonrestenotic MACE rates for noncalcified
VHTCFA were less for NCL than for culprit
lesions (2.9% vs. 8.6%, p  0.045) (Table 1).
Despite this difference the greater number of NCLs
meant that 68% of MACE occurred because of
NCLs, emphasizing that even in a PCI study, the
Figure 3. Univariate Lesion-Based Analyses of Associations Betw
(A) Nonculprit lesion (NCL) plaque subtype and nonrestenotic MACE, (
subtypes (NCL and culprit lesions) and total MACE, and (D) characteris
dence interval; HR  hazard ratio; MLA  minimum luminal area; othemajority of MACE occur because of NCL.The low number of ISR-driven MACE made an
analysis of the association between culprit lesion
factors at baseline and subsequent ISR-driven
MACE impossible. However, a pooled analysis of
all plaques (culprit and NCL) and total MACE
showed that VHTCFA remained associated with
MACE. This finding suggests that culprit
VHTCFA are associated with increased ISR-
driven MACE, although a study with sufficient ISR
MACE endpoints would be required for confirma-
tion. We also found that 3-vessel noncalcified
VHTCFA number was the only NCL factor asso-
ciated with nonrestenotic MACE on patient-based
analysis. This finding, in a population too small to
permit conventional risk factors from predicting
MACE, suggests that VH-IVUS plaque identifica-
tion may be a more useful predictor of MACE,
perhaps as it is a “downstream” marker of risk.
There are a number of important differences
between our study (VIVA) and the recently re-
ported PROSPECT study (9). First, VIVA con-
tains both stable angina and ACS patients whereas
PROSPECT contained only patients with ACS.
Second, although both studies had protocol-driven
3-vessel VH-IVUS, we acquired data both before
Plaque Subtype or Characteristics and MACE
CL plaque characteristics and nonrestenotic MACE, (C) all plaque
of all plaques (NCL and culprit lesion) and total MACE. CI  conﬁ-
breviations as in Figures 1 and 2.een
B) N
ticsand after PCI, to permit inclusion or exclusion of
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900the culprit lesions in analyses. Third, MACE def-
initions differed between studies (death, MI, or
unplanned revascularization in the VIVA study vs.
“composite of death from cardiovascular causes,
cardiac arrest, MI, or rehospitalization due to un-
stable or progressive angina” in the PROSPECT
study). The inclusion of rehospitalization in the
PROSPECT study is likely to result in higher
MACE rates. Fourth, the VHTCFA definitions
are different between studies. The PROSPECT
study required the confluent necrotic core of 10%
plaque area to be in contact with the lumen for
30° arc for 3 consecutive frames, resulting in a
higher proportion of NCL being defined as
VHTCFA in the VIVA study than in the PROSPECT
study (561 of 931 [60.2%] vs. 595 of 2,709 [22.0%],
respectively). Fifth, the VIVA study was performed
using a later iteration of the VH-IVUS software (S5
consul software version 3.1 [Volcano Corporation,
Rancho Cordova, California]) with analysis per-
formed by our core laboratory (KCRI), using the
Volcano Image Analysis Software (Volcano Corpora-
Figure 4. Univariate Patient-Based Analyses of Associations Bet
and Nonrestenotic MACE
(A) Patient clinical factors and nonrestenotic MACE, (B) stent-related
nonrestenotic MACE, (C) 3-vessel virtual histology (VH)-IVUS plaque
intervention (PCI)-related rise in biomarkers and nonrestenotic MAC
stent(s); HDL  high-density lipoprotein; hsCRP  high-sensitivity C
leukin; LDL  low-density lipoprotein; MCP  monocyte chemoattr
myocardial infarction; other abbreviations as in Figures 1 and 2.tion) version 3.0.394, whereas the PROSPECT studyused pcVH 2.1 software (Volcano Corporation). Our
findings also extend those reported in the PROS-
PECT study. We performed whole-patient analysis of
both NCL and nonrestenotic MACE, and total
plaques (culprit plus NCL) and total MACE, which
were not reported in the PROSPECT study.
Despite these differences, the VIVA and
PROSPECT studies show remarkably similar find-
ings. Both studies find that VHTCFA was the only
nonculprit lesion subtype associated with MACE
(VIVA HR: 7.53 vs. PROSPECT HR: 3.90). Both
studies also found that plaque burden 70% was
strongly associated with nonrestenotic MACE
(VIVA HR: 8.13 vs. PROSPECT HR: 8.72). Both
studies report that VHTCFA are common: VIVA
561 of 931 (60.2% of NCL) versus PROSPECT 595
of 2,709 (22.0% of NCL). Importantly, despite the
increased vulnerability of VHTCFA compared to
other plaque subtypes, the absolute event rate per
individual VHTCFA remained low. There are a
number of possible explanations for this. First, tech-
nological limitations (in particular axial resolution) limit
n Clinical, 3-Vessel Grayscale, or 3-Vessel VH-IVUS Factors
d 3-vessel grayscale intravascular ultrasound (IVUS) factors and
type and nonrestenotic MACE, and (D) percutaneous coronary
MS  bare-metal stent(s); CTnI  troponin-I; DES  drug-eluting
ctive protein; ICAM  intracellular adhesion molecule; IL  inter-
nt protein; MI 4a  post- percutaneous coronary interventionwee
an
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901defined TCFA. Second, events for which plaque rupture
is not critical (revascularization for the VIVA study and
hospitalization with progressive angina for the PROS-
PECT study) made up the majority of MACE end-
points. Finally, the lack of routine angiographic
follow-up means that some deaths in which TCFA
rupture is likely will be excluded from the analysis.
Study limitations. Although VHTCFA number was
associated with MACE, VH-IVUS findings were not
associated with death or MI. In this modern era of
aggressive interventional and pharmacotherapeutic
strategies, MACE rates in PCI studies are predomi-
nately driven by revascularization rather than by MI or
death (12), and a larger study would be required to
provide sufficient statistical power for these endpoints.
Although MACE numbers observed were relatively
small, they are consistent with our understanding of
the pathophysiology of MACE, and we believe that
use of rigorous study protocols and core laboratories
for analysis adds robustness to our conclusions. Al-
though we employed a number of univariate analyses,
our power calculation supports a significant difference
for VHTCFA only. Thus, our power calculation does
not support analyses for many of the presented results
and these should be viewed as exploratory findings.
Finally, the number of endpoints was too small to
allow reliable usage of multivariable regression.
VH-IVUS has some technological limitations, par-
ticularly the axial resolution of 100 m to 150 m (7),5. Nasu K, Tsuchikane E, Katoh O, et
al. Accuracy of in vivo coronary plaque al. A prospective naeplicate histopathologic definitions. In particular,
H-IVUS will tend to over-estimate TCFA numbers
ompared to histology, and some histologic ThCFAs
ill be classified as VHTCFAs. However, it is not
laimed that VH-IVUS–identified TCFAs are exactly
quivalent to histologically defined TCFAs, rather
hat VH-IVUS classification is valid and important if
t provides prospective prognostic information to de-
ermine the natural history of each plaque subtype.
C O N C L U S I O N S
VHTCFA was associated with nonrestenotic and
total MACE on individual plaque analysis, and non-
calcified VHTCFA was associated with nonrestenotic
and total MACE on whole-patient analysis. We
demonstrate that VH-IVUS can identify plaques at
increased risk of subsequent events, raising the possi-
bility of better risk stratification at the time of PCI.
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